pfizer and psivida

I think street is starting to realize that with $2.40 a share in cash after milestone, and $9 a share in royalties due to Psivida from Pfizer, and Psivida to get 20% of profits from Iluvien approval -which is a $1.5 to $4 billion opportunity ,that at $5 this is one of best buys in market. It is apparent that at 25x eps 2011 of 60 cents , that $15 sp can be justified. I think as 10% shareholder, Pfizer may try to force a bid in there for perhaps $10-11 which is a nice premium.